Condition
IDH1/IDH2 Mutation
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Unknown1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06666712Phase 1Recruiting
Chronic CED of TPT for Recurrent Malignant Glioma
NCT02597335Not ApplicableUnknown
Non Invasive Detection of IDH1/2 Mutation in Gliomas
Showing all 2 trials